The aptamer AS1411 against the protein nucleolin, originally developed by Aptamera for the treatment of cancer, has been shown to interact and block its interaction with the DENV capsid protein C. Furthermore, in a treatment study, this aptamer has been shown to reduce viral loads postinfection. Here, NUCLEOLIN is linked to cancer.